Doug Hayami

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

Javed Butler, Ciaran J. McMullan, Kevin J. Anstrom et al. · The Lancet · 2025 · 64 citations · Full text

Medicine, Cardiology, Internal Medicine +12

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

Faı̈ez Zannad, Christopher M. O’Connor, Javed Butler et al. · The Lancet · 2025 · 32 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17

Lower Methylation of the ANGPTL2 Gene in Leukocytes from Post-Acute Coronary Syndrome Patients

Albert Nguyen, Maya Mamarbachi, Valérie Turcot et al. · PLoS ONE · 2016 · 23 citations · Full text

Medicine, Cardiology, Molecular Biology +15

Exercise Lowers Plasma Angiopoietin-Like 2 in Men with Post-Acute Coronary Syndrome

Nathalie Thorin‐Trescases, Doug Hayami, Carol Yu et al. · PLoS ONE · 2016 · 20 citations · Full text

Medicine, Cardiology, Physiology +16

Effects of interval training on risk markers for arrhythmic death: a randomized controlled trial

Maxime Boidin, Mathieu Gayda, Christine Henri et al. · Clinical Rehabilitation · 2019 · 19 citations

Medicine, Cardiology, Rehabilitation Medicine +16